Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-07-26
2005-07-26
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S050000, C514S051000, C514S912000
Reexamination Certificate
active
06921755
ABSTRACT:
A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.
REFERENCES:
patent: 4380239 (1983-04-01), Crawford et al.
patent: 4658816 (1987-04-01), Ector, Jr.
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 4868154 (1989-09-01), Gilbard et al.
patent: 4921485 (1990-05-01), Griffiths
patent: 5021043 (1991-06-01), Becker et al.
patent: 5062831 (1991-11-01), Griffiths
patent: 5169386 (1992-12-01), Becker et al.
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5345948 (1994-09-01), O'Donnell, Jr.
patent: 5900407 (1999-05-01), Yerza et al.
patent: 23 30 902 (1975-03-01), None
patent: 08040925 (1996-02-01), None
patent: WO 97 35591 (1997-10-01), None
patent: WO 98 03177 (1998-01-01), None
patent: WO 98 03182 (1998-01-01), None
patent: WO 98 03182 (1998-01-01), None
Al-Hussein, H., et al., “Silastic Intubation in Congenital Nasolacrimal Duct Obstruction: A Study of 129 Eyes”Ophthalmic Plastic&Reconstructive Surgery 9(1):32-37 (1993).
Baker, J.C., et al.,Mutation Res., 208, 87 (1988).
Bartley, G.B., “Acquired Lacrimal Drainage Obstruction: An Etiologic Classification System, Case Reports and a Review of the Literature, Part 1”Ophthalmic Plastic Reconstructive Surgery, 8(4):237-242 (1992).
Blackburn, G.M., et al.,Nucleosides&Nucleotides, 10, 549 (1991).
Blicker, J.A., et al., “Lacrimal Sac, Conjunctival, and Nasal Culture Results in Dacryocystorhinostomy Patients,”Ophthalmic Plastic&Reconstructive Surgery, 9(1):43-46 (1993).
Bone, R., et al.,J. Biol. Chem., 261, 16410 (1986).
Brown, H., et al.,Mol. Pharmocol. 40, 648-55 (1991).
Burton, D., et al.,J. Fluorine Chem. 15, 263-266 (1980.
Casillas, T., et al.,Biochemstry, 32, 14203 (1993).
Castro, E., et al.,Br. J. Pharmacol., 100, 360 (1990).
Castro, E., et al.,Br. J. Pharmacol., 106, 833 (1992).
Castro, E., et al.,J. Biol. Chem., 270, 5098 (1995).
Castro, E., et al.,Pflugers Arch., 426, 524 (1994).
Conway, S.T., “Evaluation and Management of “Functional” Nasolacrimal Blockage: Results of a Survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery,”Ophthalmic Plastic&Reconstructive Surgery, 10(3):185-188 (1994).
Coste, H., et al.,J. Biol. Chem., 262, 12096 (1987).
Dartt, D.A., et al., “Vasoactive Intestinal Peptide-Stimulated Glycoconjugate Secretion from Conjunctival Goblet Cells,”Exp. Eye Res., 63:27-34 (1996).
Dortzbach, R.K., et al., “Silicone Intubation for Obstruction of the Nasolacrimal Duct in Children,”American Journal of Ophthalmology, 94(5):585-590 (1982).
Drutz, D., et al.,Drug Dev. Res. 37(3), 185 (1996).
Elmaleh, D.R., et al.,Proc. Natl. Acad. Sci., 81, 918 (1984).
Foster, J.A., et al., “Results of Dacryoscintigraphy in Massage of the Congenitally Blocked Nasolacrimal Duct,”Ophthalmic Plastic and Reconstructive Surgery 12(1):32-37 (1996).
Gilbard, J.P., “Dry Eye: Pharmacological Approaches, Effects, and Progress,”CLAO Journal, 22(2):141-145 (1996).
Gilbard, J.P., “Treatment of Keratoconjunctivitis Sicca in Rabbits With 3-Isobutyl-1-Methylxanthine,”Arch. Ophthalmol,. 112:1614-1616 (1994).
Gilbard, J.P., et al., “Stimulation of Tear Secretion and Treatment of Dry-Eye Disease With 3-Isobutyl-1-methylxanthine,”Arch. Ophthalmol. 109(5):672-676 (1991).
Gilbard, J.P., et al., “Stimulation of Tear Secretion by Topical Agents That Increase Cyclic Nucleotide Levels,”Investigative Ophthalmology&Visual Science, 31(7):1381-1388 (1990).
Gilbard, J.P., et al., “Osomolarity of Tear Microvolumes in Keratoconjunctivitis Sicca,”0Archives of Ophthalmology 96(4):677-681 (1978).
Gobran, L.,Am. J. Physiol. 267, L625-L633 (1994).
Gromada, J., et al., “Role of protein kinase C in the regulation of inositol phosphate production and Ca2+mobilization evoked by ATP and Acetylcholine in rat lacrimal acini,”Eur. J. Physiol. 429:578-586 (1995).
Grummt, F., et al.,Plant Mol. Bio., 2, 41 (1983).
Grymkiewicz, G. et al., “A New Generation of Ca2+Indicators with Greatly Improved Fluorescence Properties,” J. Biol. Chem. 260(6):3440-3450 (1985).
Guranowski, A., et al.,Biochemistry, 27, 2959 (1988).
Hiderman, R.H., et al.,J. Biol. Chem., 266, 6915 (1991).
Huhn, G.F., et al.,Separation and Science Technology, 28:1959-1970 (1993).
Hussain, Al H., et al.,Opthal. Plas. Recons. Surg., 9:32 (1993).
Hyde, K.J., et al., “Epidemic Keratoconjunctivitis and Lacrimal Excretory System Obstruction,”Opthamol., 95(10):1447-1449 (1988).
J. Physiol 447:103-18 (1992).
Kanavarioti, A., et al.,Tett. Lett., 32, 6065 (1991).
Kassoff, Jr., et al., “Early office-based vs late hospital-based nasolacrimal duct probing. A clinical decision analysis”Arch. Opthalmol 113(9):1168-1171 (1995).
Kim, B.K., et al.,Proc. Natl. Acad. Sci., 89, 11056 (1992).
Kimura, T., et al.,Biol. Pharm. Bull., 18, 1556 (1995).
Klein, G., et al.,Biochemistry, 27, 1897 (1988).
Klein, J.,Clin. Infect. Dis. 19, 823-33 (1994).
Knowles, M., et al.,N. Engl. J. Med. 325, 533-38 (1991).
Lazarowski, E., et al.,Brit. J. Pharm., 116, 1619-27 (1995).
Lee, V., et al.,Inv. Opthal. Vis. Sci. 38(4) (1997) abstract.
Lemp, M.A., “Is the Dry Eye Contact Lens Wearer at Risk? Yes,”Cornea 9(1):S48-S50 (1990).
Lethem, M., et al.,Am. J. Respir. Cell Mol. Biol. 9, 315-22 (1993).
Linberg, J.V., et al., “Primary Acquired Nasolacrimal Duct Obstructon A Clinicopathologic Report and Biopsy Technique,”Opthalmol., 93(8):1055-1063 (1986).
Lobaton, C.D., et al.,Eur. J. Biochem., 50, 495 (1975).
Lowe, G., et al.,Nucleosides&Nucleotides, 10, 181 (1991).
Luthje, J., et al.,Eur. J. Biochem., 173, 241 (1988).
Mason, S., et al.,Br. J. Pharmacol. 103, 1649-56 (1991).
Mauriello, Jr., J.A., et al., “Clinicopathologic Study of Lacrimal Sac and Nasal Mucosa in 44 Patients with Complete Acquired Nasolacrimal Duct Obstruction,”Opthalmic Plastic&Reconstructive Surgery, 8(1):13-21 (1992).
McKenna, C., et al.,J. Org. Chem. 46, 4574-76 (1980).
McLennan, A.G., et al.,Nucleic Acid Res., 12, 1609 (1984).
Miras-Portugal, M.T., et al.,Ann. NY Acad. Sci., 603, 523 (1990).
Morii, H., et al.,Eur. J. Biochem., 205, 979 (1992).
Moss, A. and Parsons, V.,National Center for Health Statistics, 1987:66-7, DHHS Publication No. (PHS) 86-1588 (1985).
Ng, K.E., et al.,Nucleic Acid Res., 15, 3573 (1987).
Noone, P., et al.,Am. J. Respir. Crit. Care Med. 153, A530 (1996).
Olivier, K., et al.,Am. J. Respr. Crit. Care Med. 154, 217-23 (1996).
Panchenko, V.A., et al.,Neuroscience, 70, 353 (1996).
Pintor, J., et al.,Br. J. Pharmacol. 115, 895 (1995).
Pintor, J., et al.,J. Neurochem., 64, 670 (1995).
Pohl, U., et al.Fed. Amer. Soc. Exper. Bio., Abstr. Part I, No. 1878 (1991).
Portzback, R.K., et al.,Am. J. Opthal., 94:585 (1982).
Rapaport, E., et al.,Proc. Natl. Acad. Sci., 78, 838 (1981).
Rotilan, P., et al.,FEBS, 280, 371 (1991).
Sasaki, T. et al., “Extracellular ATP activates receptor-operated cation channels in mouse lacrimal acinar cells to promote calcium influx in the absence of phosphoinositide metabolism”,FEBS 264(1):130-134 (1990).
Sasaki, T., et al., “The ATP-ind
Jacobus Karla M.
Pendergast William
Rideout Janet L.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick
LandOfFree
Method of treating dry eye disease with purinergic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating dry eye disease with purinergic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dry eye disease with purinergic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3428262